|1.||Lugnier, Claire: 5 articles (02/2015 - 10/2009)|
|2.||Grimminger, Friedrich: 4 articles (02/2012 - 01/2010)|
|3.||Keravis, Thérèse: 3 articles (02/2015 - 01/2010)|
|4.||Montorsi, Francesco: 3 articles (11/2014 - 10/2002)|
|5.||Schermuly, Ralph Theo: 3 articles (02/2012 - 01/2010)|
|6.||Weissmann, Norbert: 3 articles (01/2011 - 01/2010)|
|7.||Yan, Chen: 2 articles (03/2015 - 09/2013)|
|8.||Abusnina, Abdurazzag: 2 articles (02/2015 - 11/2011)|
|9.||Zhang, Han-Ting: 2 articles (01/2015 - 01/2015)|
|10.||Tagawa, Toshiro: 2 articles (09/2014 - 06/2003)|
|1.||Neurodegenerative Diseases (Neurodegenerative Disease)
01/01/2015 - "This review will focus on the contributions of PDEs to the interface between cognitive deficits and neuropsychiatric and neurodegenerative disorders. "
01/01/2014 - "All the PDEs are expressed in the CNS, making this gene family a particularly attractive source of new targets for the treatment of psychiatric and neurodegenerative disorders. "
12/01/2012 - "Although the latter disorder has showed a causative dysfunction of PDEs, this does not hold for the neurodegenerative disorders discussed above, in which changes in PDE levels seemingly rather represent secondary changes and compensation to prior existing dysfunction. "
12/01/2012 - "In this review, we will focus on the involvement of PDEs in neurodegenerative disorders. "
12/01/2012 - "cAMP signaling and cGMP signaling have been associated with neuroplasticity and protection, and influencing their levels in the cell by inhibition of PDEs has become a much studied target for treatment in a wide array of disorders, including neurodegenerative disorders. "
|3.||Memory Disorders (Memory Loss)
|4.||Anaphylaxis (Anaphylactic Shock)
07/01/1999 - "The survival rate was also higher in Group IV than in Group III. Pulmonary resistance (R(L)) was significantly lower in Groups I-2 and I-3 than in Group II. Dynamic pulmonary compliance (C(dyn)) was significantly higher in Group I-3 than in Group II. Heart rate and central venous pressure were similar in Groups I and II. In Groups III, IV, and V, heart rate and mean arterial pressure were comparable, but central venous pressure in Group IV was significantly lower than in Group V. In conclusion, the administration of KF19514, an inhibitor of PDEs 4 and 1, to rabbits either before or after antigen challenge improved bronchoconstriction provoked by systemic anaphylaxis with minimal concomitant cardiovascular side effects compared with aminophylline, suggesting that this agent may be useful in the treatment of systemic anaphylaxis."
01/05/2015 - "When examining the widely proven anti-tumor and anti-inflammatory activities of CAI, it is important to affirm its comprehensive inhibitory effect on PDEs, which makes it superior to some selective PDE inhibitors in a way. "
01/01/2015 - "Alterations in expression of PDEs and PDE-gene mutations (especially mutations in PDE6, PDE8B, PDE11A, and PDE4) have been implicated in various diseases and cancer pathologies. "
09/01/2014 - "The role of PDEs in malignant tumor cells is still uncertain. "
04/01/2014 - "Mouse models have been developed that point to wide developmental effects of PDEs from heart function to reproduction, to tumors, and beyond. "
12/01/2011 - "This review focuses on the possible function of PDEs in a variety of tumors, primarily in endocrine glands, both in tumor predisposition and as potential therapeutic targets."
|1.||Phosphoric Diester Hydrolases (Phosphodiesterases)
|6.||Phosphodiesterase 4 Inhibitors
|7.||Small Interfering RNA (siRNA)
|2.||Continuous Ambulatory Peritoneal Dialysis (CAPD)